Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

570
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Routine venoarterial extracorporeal membrane oxygenation for acute myocardial infarction-related cardiogenic shock: what we know and don't know.

Intensive care medicine·2024
Same author

Ventricular septal defect complicating acute myocardial infarction: diagnosis and management. A Clinical Consensus Statement of the Association for Acute CardioVascular Care (ACVC) of the ESC, the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC and the ESC Working Group on Cardiovascular Surgery.

European heart journal·2024
Same author

Impact of Blood Pressure Targets in Patients With Heart Failure Undergoing Postresuscitation Care: A Subgroup Analysis From a Randomized Controlled Trial.

Circulation. Heart failure·2024
Same author

Vasodilators for Acute Heart Failure - A Systematic Review with Meta-Analysis.

NEJM evidence·2024
Same author

Biomarker patterns in patients with cardiogenic shock versus septic shock.

International journal of cardiology. Heart & vasculature·2024
Same author

Acute kidney injury after out-of-hospital cardiac arrest.

Critical care (London, England)·2024

Related Experiment Video

Updated: Jun 24, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K

Future for cardiogenic shock research.

Jacob Eifer Møller1,2, Holger Thiele3, Christian Hassager1,4

  • 1Department of Cardiology, Copenhagen University Hospital, Copenhagen.

Current Opinion in Critical Care
|June 6, 2024
PubMed
Summary
This summary is machine-generated.

Future research in cardiogenic shock will leverage artificial intelligence and machine learning for patient phenotyping. Novel trial designs will address challenges in treating this critical condition.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

712

Related Experiment Videos

Last Updated: Jun 24, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

712

Area of Science:

  • Cardiology
  • Medical Research
  • Clinical Trials

Background:

  • Cardiogenic shock is a life-threatening condition with complex challenges in research and treatment.
  • Heterogeneity in patient populations complicates clinical trial design and interpretation of results.
  • Ethical considerations, including informed consent and timely intervention, pose significant hurdles for research in acute settings.

Purpose of the Study:

  • To outline future research directions in cardiogenic shock.
  • To discuss innovative study designs for investigating this condition.
  • To highlight advancements in understanding and managing cardiogenic shock.

Main Methods:

  • Review of current literature on cardiogenic shock research.
  • Exploration of artificial intelligence (AI) and machine learning (ML) for patient phenotyping.
  • Discussion of proteomic and metabolomic approaches for molecular mechanism discovery.
  • Analysis of mechanical circulatory support and anti-inflammatory strategies.
  • Evaluation of adaptive platform trial designs.

Main Results:

  • Cardiogenic shock research is hindered by patient heterogeneity and ethical complexities.
  • AI and ML offer potential for precise patient phenotyping.
  • Proteomics and metabolomics can elucidate underlying molecular pathways.
  • Mechanical circulatory support and inflammation targeting are key future research areas.
  • Adaptive platform trials represent a promising approach for future clinical studies.

Conclusions:

  • Advanced phenotyping using AI/ML is crucial for future cardiogenic shock research.
  • Investigating molecular mechanisms via proteomics and metabolomics will enhance understanding.
  • Focus on mechanical circulatory support and inflammation modulation is warranted.
  • Novel trial designs, such as adaptive platform trials, are essential for efficient research.
  • Addressing heterogeneity and ethical challenges is key to advancing cardiogenic shock treatment.